LO RE, Oriana, C. FUSILLI, F. RAPPA, M. VAN HAELE, J. DOUET, J. PINDJAKOVA, S.W. ROCHA, I. PATA, Barbora VALČÍKOVÁ, Stjepan ULDRIJAN, R.S. YEUNG, C.A. PEIXOTO, T. ROSKAMS, M. BUSCHBECK, T. MAZZA and M. VINCIGUERRA. Induction of cancer cell stemness by depletion of macrohistone H2A1 in hepatocellular carcinoma. Hepatology. Philadelphia: Saunders, 2018, vol. 67, No 2, p. 636-650. ISSN 0270-9139. Available from: https://dx.doi.org/10.1002/hep.29519.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Induction of cancer cell stemness by depletion of macrohistone H2A1 in hepatocellular carcinoma
Authors LO RE, Oriana (380 Italy, belonging to the institution), C. FUSILLI (380 Italy), F. RAPPA (380 Italy), M. VAN HAELE (56 Belgium), J. DOUET (724 Spain), J. PINDJAKOVA (203 Czech Republic), S.W. ROCHA (76 Brazil), I. PATA (233 Estonia), Barbora VALČÍKOVÁ (203 Czech Republic, belonging to the institution), Stjepan ULDRIJAN (203 Czech Republic, belonging to the institution), R.S. YEUNG (840 United States of America), C.A. PEIXOTO (76 Brazil), T. ROSKAMS (56 Belgium), M. BUSCHBECK (724 Spain), T. MAZZA (380 Italy) and M. VINCIGUERRA (826 United Kingdom of Great Britain and Northern Ireland, guarantor).
Edition Hepatology, Philadelphia, Saunders, 2018, 0270-9139.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30219 Gastroenterology and hepatology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 14.971
RIV identification code RIV/00216224:14110/18:00102119
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1002/hep.29519
UT WoS 000422694900020
Keywords in English histone variants; epigenetics; hepatocellular carcinoma; cancer stem cells
Tags 14110513, EL OK, rivok
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 10/2/2019 14:50.
Abstract
Hepatocellular carcinomas (HCC) contain a subpopulation of cancer stem cells (CSCs), which exhibit stem cell-like features and are responsible for tumor relapse, metastasis, and chemoresistance. The development of effective treatments for HCC will depend on a molecular-level understanding of the specific pathways driving CSC emergence and stemness. MacroH2A1 is a variant of the histone H2A and an epigenetic regulator of stem-cell function, where it promotes differentiation and, conversely, acts as a barrier to somatic-cell reprogramming. Here, we focused on the role played by the histone variant macroH2A1 as a potential epigenetic factor promoting CSC differentiation. In human HCC sections we uncovered a significant correlation between low frequencies of macroH2A1 staining and advanced, aggressive HCC subtypes with poorly differentiated tumor phenotypes. Using HCC cell lines, we found that short hairpin RNA-mediated macroH2A1 knockdown induces acquisition of CSC-like features, including the growth of significantly larger and less differentiated tumors when injected into nude mice. MacroH2A1-depleted HCC cells also exhibited reduced proliferation, resistance to chemotherapeutic agents, and stem-like metabolic changes consistent with enhanced hypoxic responses and increased glycolysis. The loss of macroH2A1 increased expression of a panel of stemness-associated genes and drove hyperactivation of the nuclear factor kappa B p65 pathway. Blocking phosphorylation of nuclear factor kappa B p65 on Ser536 inhibited the emergence of CSC-like features in HCC cells knocked down for macroH2A1. Conclusion: The absence of histone variant macroH2A1 confers a CSC-like phenotype to HCC cells in vitro and in vivo that depends on Ser536 phosphorylation of nuclear factor kappa B p65; this pathway may hold valuable targets for the development of CSC-focused treatments for HCC.
PrintDisplayed: 14/5/2024 15:52